While playing an integral role in biotechnology and medicine, cryopreservation (CP) is often viewed as a “simple tool” and is overlooked as a critical and evolving component of cell and tissue bioprocessing. Despite this, cryopreservation serves as an enabling technology in numerous areas including the latest cell therapies. For example, over one third of the cells used in clinical trials are cryopreserved using the traditional methods, which in many cases yield suboptimal outcomes. Further, researchers still rely on the assessment of cell survival immediately post-thaw (within a few hours), and fail to account for the impact of cryopreservation-induced delayed-onset cell death (CIDOCD) which continues to impact survival from hours to days post-thaw.
Tag: <span>high-throughput screening</span>
The search for new and more effective drugs is a complex and challenging endeavor requiring a number of strategies for identifying and processing new drug candidates. A common tool used in this search is high-throughput screening (HTS) of a large library of small molecular weight compounds. In each of our HTS campaigns, more than 500,000 compounds are tested for biological activity against one of our many molecular disease targets in order to identify compounds of potential therapeutic interest. High-throughput screens can be divided into two major types: those using cells, and those not using cells. At least 50% of our screens are cell-based and require a consistent, uniform supply of cells throughout the screening campaign. The provision of the cells is a primary consideration in our cell-based assays and therefore, an automated cell culture laboratory was included in our HTS facility. This laboratory serves two functions: the preparation of cell banks, and the daily provision of microtiter plates containing cells for the HTS…